Sertraline Hydrochloride Tablet
Product Images NDC 72865-205

Product Visual Gallery

This gallery contains 26 technical images submitted to the FDA as part of the official labeling for Sertraline Hydrochloride (NDC 72865-205). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xlcare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100 mg (100mg 180s)

Label for Sertraline Hydrochloride Tablets, USP 100 mg oral tablets by XLCare Pharmaceuticals, Inc. The label states a quantity of 180 tablets and includes NDC 72865-207-18. It notes storage conditions between 20°C to 25°C, manufacturing by Ascent Pharmaceuticals, Inc., and that the product is for prescription use only.*

FDA Label Image

100 mg (100mg 30s)

Label for Sertraline Hydrochloride Tablets, USP 100 mg by XLCare Pharmaceuticals, Inc. The film-coated tablets contain sertraline hydrochloride equivalent to 100 mg sertraline. The package contains 30 tablets. It includes storage instructions (20°C to 25°C), manufacturing information for Ascent Pharmaceuticals, Inc., and dispensing guidance for pharmacists. The label features the NDC 72865-207-30 and emphasizes prescription use only.*

FDA Label Image

100 mg (100mg 500s)

Label for Sertraline Hydrochloride Tablets, USP 100 mg oral tablets by XLCare Pharmaceuticals, Inc. The label shows a 500 tablet bottle with NDC 72865-207-05, indicating the product contains 100 mg sertraline hydrochloride per tablet, manufactured by Ascent Pharmaceuticals, Inc. The label notes storage instructions and dispensing guidelines, specifying the product is prescription only.*

FDA Label Image

100 mg (100mg 90s)

Sertraline Hydrochloride Tablets, USP 100 mg oral tablet label from XLCare Pharmaceuticals, Inc. The label states each film-coated tablet contains 111.9 mg sertraline hydrochloride equivalent to 100 mg sertraline. It includes storage instructions, manufacturer information (Ascent Pharmaceuticals, Inc., Central Islip, NY), and package size of 90 tablets. The label features a barcode and designated areas for lot and expiration dates.*

FDA Label Image

25 mg (25 mg 500s)

Label for Sertraline Hydrochloride Tablets USP 25 mg by XLCare Pharmaceuticals, Inc. The label shows a 500 tablet count and indicates that each film-coated tablet contains 28 mg sertraline hydrochloride equivalent to 25 mg sertraline. It includes storage instructions and manufacturer information.*

FDA Label Image

25 mg (25mg 180s)

Label for Sertraline Hydrochloride Tablets, USP 25 mg oral tablets from XLCare Pharmaceuticals, Inc. The label includes the NDC 72865-205-18, package size of 180 tablets, and notes the product is Rx only. It states each film-coated tablet contains sertraline hydrochloride equivalent to 25 mg sertraline. Manufactured by Ascent Pharmaceuticals, Inc. and labeled by XLCare Pharmaceuticals, Inc.*

FDA Label Image

25 mg (25mg 30s)

Label for Sertraline Hydrochloride Tablets USP, 25 mg strength, oral tablets by XLCare Pharmaceuticals Inc. The label states each tablet contains 28 mg sertraline hydrochloride equivalent to 25 mg sertraline. The package contains 30 tablets. Storage instructions, manufacturer, and distributor information are also present.*

FDA Label Image

25 mg (25mg 90s)

Label for Sertraline Hydrochloride Tablets USP 25 mg, an oral tablet prescription drug by XLCare Pharmaceuticals, Inc. The label states it contains 90 tablets. Each film-coated tablet has 28 mg sertraline hydrochloride, equivalent to 25 mg sertraline. Storage instructions, manufacturer details (Ascent Pharmaceuticals, Inc.), and a barcode are visible on the label.*

FDA Label Image

50 mg (50mg 180s)

Carton label for Sertraline Hydrochloride Tablets, USP 50 mg, by XLCare Pharmaceuticals, Inc. The label states 180 tablets, oral dosage form. It includes storage information, manufacturer details (Ascent Pharmaceuticals, Inc.), and notes that each film-coated tablet contains 56 mg sertraline hydrochloride equivalent to 50 mg sertraline. Rx only.*

FDA Label Image

50 mg (50mg 30s)

Sertraline Hydrochloride Tablets, USP 50 mg oral tablets label from XLcare Pharmaceuticals, Inc. The package contains 30 tablets. The label states each film-coated tablet contains 56 mg sertraline hydrochloride equivalent to 50 mg sertraline. Manufactured by Ascent Pharmaceuticals, Inc. and labeled for XLcare Pharmaceuticals, Inc.*

FDA Label Image

50 mg (50mg 500s)

Label for Sertraline Hydrochloride Tablets, USP 50 mg, oral tablets by XLCare Pharmaceuticals, Inc. The label states the package contains 500 tablets and highlights that each film-coated tablet contains 56 mg sertraline hydrochloride equivalent to 50 mg sertraline. It includes storage instructions and manufacturing details for Ascent Pharmaceuticals, Inc. and XLCare Pharmaceuticals, Inc.*

FDA Label Image

50 mg (50mg 90s)

Label for Sertraline Hydrochloride Tablets USP 50 mg by XLCare Pharmaceuticals, Inc. The oral tablet package contains 90 tablets. The label notes each film-coated tablet contains 56 mg sertraline hydrochloride equivalent to 50 mg sertraline. Storage instructions specify 20°C to 25°C. Manufactured by Ascent Pharmaceuticals, Inc., and labeled for XLCare Pharmaceuticals, Inc.*

FDA Label Image

Serious Symptoms (Serioussymptoms)

A partial drug facts or warning text panel listing potential symptoms such as high fever, rapid changes in heart rate or blood pressure, uncontrolled muscle spasms, confusion, stiff muscles, and loss of consciousness (passing out). The text is in bullet points but incomplete, showing only part of a larger safety or side effects section.*

FDA Label Image

Common Side Effects (Commonsideeffect)

A text panel listing side effects of a medication that include nausea, loss of appetite, diarrhea, indigestion, increased sweating, tremor or shaking, agitation, changes in sleep habits including increased sleepiness or insomnia, sexual problems such as decreased libido and ejaculation failure, feeling tired or fatigued, and anxiety.*

FDA Label Image

Health Problems (Healthproblem)

Text panel listing medical conditions and symptoms under caution or warnings, including liver problems, heart problems, bipolar disorder or mania, kidney problems, seizures or convulsions, low sodium levels, history of stroke, high blood pressure, and bleeding problems.*

FDA Label Image

Structure (Struct)

Chemical structure of sertraline hydrochloride, showing its molecular framework including the bicyclic system and dichlorophenyl group associated with the sertraline molecule and the hydrochloride component.*

FDA Label Image

Symptoms 1 (Symptoms 1)

A partial text panel listing behavioral and emotional symptoms related to the use of sertraline hydrochloride tablets. It includes cautionary points such as attempts to commit suicide, aggressive behavior, new or worsening depression, agitation, increased activity or talking, dangerous impulses, suicidal thoughts, anxiety, panic attacks, trouble sleeping, and other mood changes.*

FDA Label Image

Symptoms 2 (Symptoms 2)

A partial text panel listing symptoms or side effects related to sertraline hydrochloride, including agitation, hallucinations, coma, changes in mental status, racing heartbeat, blood pressure irregularities, coordination problems, muscle twitching, nausea, vomiting, diarrhea, sweating, fever, and muscle rigidity.*

FDA Label Image

Symptoms 4 (Symptoms 4)

A text panel listing potential side effects or symptoms including greatly increased energy, racing thoughts, unusually grand ideas, severe trouble sleeping, reckless behavior, excessive happiness or irritability, and talking more or faster than usual.*

FDA Label Image

Symptoms 8

A text panel listing potential side effects including headache, weakness or feeling unsteady, confusion, problems concentrating or thinking, and memory problems. The content appears to focus on specific symptoms or adverse reactions associated with the medication.*

FDA Label Image

Table1

A table presenting the recommended daily dosage of sertraline hydrochloride for various indications including MDD, OCD, PD, PTSD, and SAD in adult and pediatric patients. It details starting doses and therapeutic ranges, differentiating doses by indication and age groups in pediatric OCD patients.*

FDA Label Image

Table 2 (Table2)

A data table displaying risk differences in the number of cases of suicidal thoughts or behaviors in pooled placebo-controlled antidepressant trials, categorized by age range. It compares drug versus placebo effects, showing increases in cases for patients under 25 and decreases for patients 25 and older.*

FDA Label Image

Table 3 (Table3)

Table presenting common adverse reactions in pooled placebo-controlled trials for sertraline hydrochloride compared to placebo in adults with various disorders. The table lists adverse reactions by disorder category and shows the percentage of patients experiencing each reaction with sertraline hydrochloride (N=3066) versus placebo (N=2293). Categories include cardiac, eye, gastrointestinal, general disorders, metabolism, nervous system, psychiatric, reproductive, and skin disorders.*

FDA Label Image

Table 4 (Table4)

A data table displaying the most common sexual adverse reactions occurring at rates of 2% or higher and at least twice the placebo rate in men or women from pooled controlled trials of sertraline hydrochloride. It compares percentages of sexual side effects in men and women treated with sertraline hydrochloride versus placebo from studies on various conditions including MDD and OCD.*

FDA Label Image

Table 5 (Table5)

Table presenting clinically-significant drug interactions with sertraline hydrochloride, detailing clinical impacts, interventions, and examples of interacting drugs such as Monoamine Oxidase Inhibitors (MAOIs), pimozide, serotonergic drugs, drugs affecting hemostasis, drugs highly bound to plasma protein, CYP2D6 substrates, phenytoin, and drugs that prolong the QTc interval.*

FDA Label Image

Treatment (Treatment)

A text panel listing conditions addressed by the medication, including Major Depressive Disorder (MDD), Panic Disorder, Social Anxiety Disorder, Obsessive Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD), and Premenstrual Dysphoric Disorder (PMDD).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.